RxDoctor Payments Data

Justin Holtzman, MD

Internal Medicine · Brookline, MANPI 1669769501

Payments from drug & device makers

$11,378in general payments, 2019–2025

Across 266 payments — averaging $42.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$5K
  • AbbVie$1K
  • Gilead$690
  • Pfizer$534
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$440
  • Johnson & Johnson$367
  • plus $3K from 38 others

What the payments were for

  • Speaking & faculty fees$5,46548%
  • Food & beverage$5,91352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,378 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$145,140
Medicare patients
491
Services billed
1,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$22,982
OzempicSemaglutide12$16,619
Rosuvastatin Calcium26$1,281
Oxycodone Hcl65$1,165
Vancomycin Hcl11$1,114
Atorvastatin Calcium108$1,083
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine15$983
Gabapentin80$982
Metoprolol Succinate63$970
Albuterol Sulfate HfaAlbuterol Sulfate38$918
Escitalopram Oxalate26$629
Levothyroxine Sodium54$534
Omeprazole35$530
Cefpodoxime Proxetil14$396
Lisinopril50$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$534$22,98217 claims
Novo NordiskOzempic$118$16,61912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Brookline

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →